AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03703882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edasalonexent
Description: 100 mg/kg/day
Study NCT03703882 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04584528 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Electronic Health Record (EHR) Embedded Individualized Pain Plan (IPP)
Description: The IPPs will be developed by the Sickle Cell Disease providers at each study site based on patients' outpatient chronic opioid use and analgesic agent normally required for treatment of VOE in the ED. The Sickle Cell Disease provider will review the IPP with the patient, then upload the IPP to the patient's EHR in a location that will be accessible by the patient and ED provider. Each participating site will train patients and Emergency Department (ED) providers on how to access the IPP in the Electronic Health Record. The following required elements will be included in the EHR-embedded IPP:~* Genotype~* Individual pain plan-preferred analgesic agent, route, dose and dosing interval, last update time~* Name and contact information for the SCD provider~If the enrolled patient has a VOE visit at a nonparticipating ED, the patient will be able to access their IPP via the web or the patient portal app through their EHR. However, data will not be collected from these visits.
Study NCT04451980 — intervention group
Intervention type: PROCEDURE
Intervention: Subcutaneous adipose tissue biopsy
Description: Percutaneous adipose tissue biopsy
Study NCT04451980 — intervention group
Intervention type: RADIATION
Intervention: CT scan
Description: CT scan of chest and abdomen without contrast
Study NCT04451980 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Oral glucose tolerance test
Description: Ingestion of 75g of oral glucose syrup and measurement of blood glucose and insulin at time 0, 15 min, 30 min, 60 min, 90 min, and 120 min.
Study NCT04451980 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood collection
Description: Fasting blood collection for plasma cytokines and T cell phenotypes.
Study NCT03415295 — intervention group
Intervention type: OTHER
Intervention: Plasma TMAO concentration
Description: Plasma TMAO concentrations were determined by stable isotope dilution liquid chromatography with online electrospray ionization tandem mass spectrometry on an AB SCIEX 4500 triple quadrupole mass spectrometer
Study NCT03053700 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bromonide 0.33% gel
Description: Patients would be treated with full face application of bromonide 0.33% gel once daily for three months.
Study NCT03053700 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intense Pulsed Light (M22)
Description: Half of the patients' face would be subjected to three IPL treatment sessions three weeks apart from each other.
Study NCT02019576 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Stereotactic radiotherapy
Description: SRT to all areas of oligo-progression as follows: BRAIN: 20-24 Gy in 1 fraction if \< 2 cm,18 Gy in 1 fraction if 2-3 cm,15 Gy in 1 fraction for 3-4 cm, alternatively 25-30 Gy in 5 fractions can be used; SPINE: 18-24 Gy in 1-2 fractions,24 Gy in 3 fractions or 30-40 Gy in 5 fractions; NON-SPINE BONE: 30-40 Gy in 5 fractions; LUNG: 48-60 Gy in 4 fractions or 54-60 Gy in 3 fractions for peripheral lung tumours,50 Gy in 5 fractions or 60 Gy in 8 fractions for central lung tumours; LIVER: 30-60 Gy in 3-6 fractions,higher doses for central liver lesions and lower doses for peripheral liver lesions depending on proximity to adjacent organ (stomach, small bowel, large bowel or kidney); ADRENAL OR KIDNEY TUMOURS: 30-40 Gy in 5 fractions; LYMPHADENOPATHY: 30-40 Gy in 5 fractions.
Study NCT03988348 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: infraumbilical transverse incision
Description: a 10 mm infraumbilical transverse incision will be done to allow trocar to be inserted without undue resistance from the skin so that the trocar will pass through the fascia and the peritoneum with ease
Study NCT03988348 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intraumbilical incision
Description: right sided curved longitudinal intraumbilical incision will be performed for initial intraperitoneal access
Study NCT03556553 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vertise Flow
Description: Composite resin
Study NCT01203969 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single port laparoscopic surgery
Description: laparoscopic surgery in which all the instrument was entered into the abdominal cavity through the single port in the umbilicus
Study NCT01203969 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional laparoscopic surgery
Description: laparoscopic surgery in which each of the instrument were entered into the abdominal cavity through the multiple port in multiple quadrants of abdomen
Study NCT03556553 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LuxaFlow
Description: Composite resin
Study NCT03556553 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Teco Adhesive
Description: Adhesive system
Study NCT03947489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarpogrelate HCL 300mg
Description: a single oral dose administration in healthy volunteers under fasting condition
Study NCT03947489 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sarpogrelate HCL 300mg
Description: a single oral dose administration in healthy volunteers under fasting condition
Study NCT03662880 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Cardiac Magnetic Resonance
Description: Imaging modality used to detection thrombus in left atrium
Study NCT03662880 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Trans-esophageal echo
Description: a procedure in which the ultrasound probe is inserted into the esophagus and ultrasonographic images are obtained of the heart using echo and color Doppler images.
Study NCT02329964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Sugammadex 2mg/kg was injected to patients to R-S group, as reversal of neuromuscular blockade.
Study NCT02329964 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: Neostigmine (pyridostigmine) 0.2 mg/kg mg was injected to patients to S-C-N group, as reversal of neuromuscular blockade.
Study NCT03328702 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure
Description: Apex XT Fit CPAP Machine
Study NCT00366964 — intervention group
Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Laser Treatment
Description: The laser treatment involves the use of an FDA approved laser device (510K Clearance certificate) for hair removal and treatment of leg veins for females having skin types III - VI. The pulses are of appropriate energy and pulse duration based on the skin type.
Study NCT00366964 — intervention group
Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Wave Light laser device for skin treatment
Description: To determine efficacy of FDA approved Laser treatment for hair removal and leg veins. The Mydon Wavelight is a Long Pulsed Nd Yag Laser, Class IV 1064 nm 55W
Study NCT02700724 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Immediate Surgery
Study NCT02700724 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Observation
Study NCT02700724 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surveillance Cystoscopy and Urinary Cytology
Description: Cytology and cystoscopy are done at the same time
Study NCT01806350 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT01806350 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT01806350 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard follow-up care
Description: Receive usual care
Study NCT01806350 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention
Description: Undergo PFMT
Study NCT04031911 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydroposturotherapy
Description: Hydroposturotherapy combines:~* posturotherapy (patient placed upside down with water jets sent to the kidneys)~* lumbar percussion~* hyperdiuresis: prescribed quantities of water to be absorbed by the patient
Study NCT04031911 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Standard support in urology
Description: Dispensing of AFU plugs Dietary advice
Study NCT00575198 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No drainage threshold
Description: Removal of the thoracostomy tube independently of the amount of fluid that drained from the tube in the prior 24 hours
Study NCT00575198 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Drainage <2 mL/kg
Description: Removal of the thoracostomy tube only if the drainage from the tube in the prior 24 hours is less than 2 mL/kg of the patient's ideal body weight
Study NCT03479996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marcaine 0.5 % Injectable Solution
Description: Intra -operative injection into obturator membrane
Study NCT01035775 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inspection during insertion
Description: The colonic mucosa will be inspected for lesions during insertion of the instrument, and during withdrawal of the instrument.
Study NCT01035775 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inspection during withdrawal
Description: The colonic mucosa will be inspected for lesions only during withdrawal of the instrument from the cecum. The instrument will be inserted to the cecum without deliberate inspection.
Study NCT03023527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study NCT03023527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Study NCT03023527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study NCT03023527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elotuzumab
Study NCT02021084 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: probiotic
Description: Probiotics group - patients will received probiotics Bio -25 including 11 types of bacteria total of 25 billion germs in each capsule, patients will received one capsule a day for 3 month.
Study NCT02021084 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo group - patients will received placebo patients will received one capsule a day for 3 month.
Study NCT03785925 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bempegaldesleukin
Description: Specified dose on specified days
Study NCT03785925 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study NCT01975740 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sham manual diaphragm release technique
Study NCT01975740 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The manual diaphragm release technique
Description: To perform the technique the volunteer was placed in supine position with limbs relaxed. Positioned behind the head of the volunteer, the therapist performed manual contact (pisiform, ulnar edge and the last three fingers) with the underside of the costal cartilage of the 7th, 8th, 9th and 10th rib, and guiding forearms toward the shoulders of the corresponding side. In the inspiratory phase, the therapist gently pulled the points of contact with both hands, in the direction of the head, yet slightly lateral, accompanying the elevation movement of the ribs. During exhalation, the therapist deepened contact toward the inner costal, maintaining resistance throughout the inspiratory phase. In the breaths following, the therapist sought to gain traction and smooth increase in the deepening of contacts. This maneuver was performed in two sets of ten deep breaths, with a one minute interval between them.
Study NCT06169475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Hydrochloride
Description: The continuous intravenous infusion of dexmedetomidine (0.1mg/ml) will start at 0.1ug/kg/h, increasing every 20 minutes by a step change of 0.05-0.2ug/kg/h to reach the target heart rate with the expectation that this should be within 12 hours. The infusion will be reduced by step change, and if necessary, ultimately stopped if the heart rate fall below 80b.p.m..
Study NCT06169475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmolol Hydrochloride
Description: The continuous intravenous infusion of esmolol (10mg/ml) will start at 20mg/h, increasing every 20 minutes by a step change of 20mg/h to reach the target heart rate with the expectation that this should be within 12 hours. The infusion will be reduced by step change, and if necessary, ultimately stop if the heart rate fall below 80b.p.m..
Study NCT00954720 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: There is no intervention on this trial
Study NCT01423162 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention (with Vit C then without Vit C)
Description: Fortified oat drink with vitamin C followed by fortified oat drink without vitamin C
Study NCT01423162 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention (without Vit C followed by with Vit C)
Description: Fortified oat drink without vitamin C followed by fortified oat drink with vitamin C
Study NCT01880671 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Inactive Migraine Medical Device
Study NCT01880671 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Migraine Medical Device
Study NCT03870542 — intervention group
Intervention type: PROCEDURE
Intervention: kidney transplantation
Description: Kidney transplant for end-stage renal disease from deceased kidney donors
Study NCT02361502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirabegron
Study NCT02361502 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT02029859 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Polygraphic examination
Description: Polygraphic examination between 30 and 36 weeks of amenorhea
Study NCT02657395 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PriMatrix
Description: Use of PriMatrix under a coronal positioned flap to obtain root coverage.
Study NCT02651168 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: aflibercept
Description: EYLEA (aflibercept, solution for intravitreal injection) is a recombinant fusion protein consisting of portions of human Vascular Endothelial Growth Factor (VEGF) receptor 1 and 2 extracellular domains fused to the Fc portion of human IgG1 and formulated as an iso-osmotic solution for intravitreal administration. Aflibercept is produced in Chinese hamster ovary (CHO) K1 cells by recombinant DNA technology.
Study NCT00820677 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DVD/Video
Description: One DVD or Video will be watched by all parents of newborns enrolled into the experimental group.
Study NCT03401515 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol Hydrochloride 1 MG/ML
Description: Propranolol 1 mg every 6 hrs in the first 24 hrs after isolated blunt traumatic brain injury
Study NCT03401515 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal Saline 1 ml every 6 hrs
Study NCT04940104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox Injectable Product
Description: Botox is a well known neurotoxin that is derived from the bacterium clostridium botulinium. Its therapeutic applications are variable and well documented, alongside its cosmetic applications. There are seven known serotypes of Botox, from A to G, but only two types; A \&B, are available for medical and cosmetic uses.
Study NCT04639856 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary Artery Bypass Grafting
Description: on-pump vs off pump Coronary artery Bypass Grafting
Study NCT03978455 — intervention group
Intervention type: BEHAVIORAL
Intervention: Learn, Connect, and Quit Mobile Application
Description: The Learn, Connect, and Quit (LCQ) Mobile Application is an application for electronic tablets that can: assess smokers' interest in quitting; answer smokers' questions about smoking, quitting, and available treatments; provide information about treatment options; communicate information about patients' smoking status, concerns, and treatment interest to their provider; and connect patients with treatment options including the Wisconsin Tobacco Quitline (WTQL), and other smoking intervention resources provided by their healthcare system.
Study NCT02463409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Theophylline
Description: 24 hour infusion of IV theophylline
Study NCT03199820 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cook cervical balloon
Description: trans-cervical balloon catheter for out-patient labour induction
Study NCT03199820 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prostin E2 Vaginal Suppository
Description: Propess Vaginal suppository for out-patient Labour induction
Study NCT00870051 — intervention group
Intervention type: DEVICE
Intervention: Endurant Stent Graft
Description: Endurant Stent Graft implantation
Study NCT02075372 — intervention group
Intervention type: OTHER
Intervention: Data registration
Description: Patients diagnosed with the presence of one or more chronic total occlusions (CTOs) and who will receive treatment via percutaneous coronary intervention (PCI), which is standard medical practice for these types of lesions. This study will collect data on the patients' demographics, CTO characteristics, procedure and outcome. This will be done in the form of a registry
Study NCT04412850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: Magnesium and placebo (Normal Saline) will be prepared as solutions of identical volume and appearance. All patients will be randomized and blind to treatment.~All patients will have pretreatment Electrogram (ECG), serum biochemistry and serum Magnesium levels. Serum Magnesium levels will also be measured at 48 hours. Blood pressure, heart rate, respiratory rate and serious adverse events will be monitored at baseline, 15 minutes, and 12, 24 and 48 hours after infusion. Magnesium will be given intravenously with a loading dose of 4 g in 50 mL saline over a 15-minute period and 16 g in 100 mL over a 24-hour period in a continuous-infusion form.~Follow-up visits will be conducted by the same investigators, and repeated scores on the NIH Stroke Scale will be obtained at 24 hours, 48 hours post admission and on the day of discharge.
Study NCT04412850 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Magnesium Sulfate
Description: Magnesium and placebo (Normal Saline) will be prepared as solutions of identical volume and appearance. All patients will be randomized and blind to treatment.~All patients will have pretreatment Electrogram (ECG), serum biochemistry and serum Magnesium levels. Serum Magnesium levels will also be measured at 48 hours. Blood pressure, heart rate, respiratory rate and serious adverse events will be monitored at baseline, 15 minutes, and 12, 24 and 48 hours after infusion. Magnesium will be given intravenously with a loading dose of 4 g in 50 mL saline over a 15-minute period and 16 g in 100 mL over a 24-hour period in a continuous-infusion form.~Follow-up visits will be conducted by the same investigators, and repeated scores on the NIH Stroke Scale will be obtained at 24 hours, 48 hours post admission and on the day of discharge.
Study NCT02693561 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Deep Breathing Exercises
Description: Technical Deep Breathing: Deep breathing is to deep breath and slowly through the nostrils until total lung capacity. At the end of inspiration is kept a few seconds of apnea and started after the expiration slowly. End-expiratory apnea will remain a few seconds to start new inspiration cycle. With this process the individual breathe about 6 times per minute. Breath learning occurs through visual feedback. In the intervention group will be held deep breathing for 10 minutes. Subjects will be instructed to deep breath for 10 minutes 2 times a day for 15 days beyond the period in which they cleft, which is one of the symptoms of withdrawal syndrome. Control and frequency of deep breathing will be obtained weekly through specific daily fill, which will be provided weekly.
Study NCT02693561 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Help Book
Description: Reading the self-help book.
Study NCT03784547 — intervention group
Intervention type: DRUG
Intervention: Ocrelizumab
Description: already described
Study NCT01875783 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OCT imaging
Description: Optical coherence tomography (OCT) imaging is a noninvasive, rapid, and readily performed method for evaluating the anatomy of the central retina.
Study NCT01227486 — intervention group
Intervention type: DEVICE
Intervention: Ultrasound
Description: Ultrasound scan just proximal to the suprasternal notch during intubation and ultrasound scan of both lungs during ventilation
Study NCT01916876 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Integrated medical follow-up package
Description: At discharge, patients will receive a discharge plan by their attending caregiver.~1. On day 3 they will be contacted telephonically to:~   i) Discuss their discharge diagnosis and medications ii) Arrange specialist clinic follow-up booking for 2 weeks iii) Reemphasise drug compliance~2. Reminders via SMS to attend there OPD appointment(s)~3. Medical out-patient review at 2-weeks and 6 weeks if required~4. Medical telephonic hot-line for advice